Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beilei Wang

Showing results (161-170 of 173) with videos related to

Pageof 18
Sort By:
European Journal of Medicinal Chemistry|June 20, 2017
Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitorsBeilei Wang, Yuanxin Deng, Yongfei Chen, et al.
European Journal of Medicinal Chemistry|October 15, 2018
Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemiaXuesong Liu, Beilei Wang, Cheng Chen, et al.
Journal of Medicinal Chemistry|February 1, 2017
Discovery of 2-((3-Acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow Kinase in the X Chromosome (BMX) Kinase InhibitorXiaofei Liang, Fengchao Lv, Beilei Wang, et al.
Journal of Medicinal Chemistry|August 23, 2016
Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I "Gatekeeper" Mutant of cKIT KinaseBinhua Li, Aoli Wang, Juan Liu, et al.
Oncotarget|September 15, 2016
Ibrutinib targets mutant-EGFR kinase with a distinct binding conformationAoli Wang, Xiao-E Yan, Hong Wu, et al.
Journal of Medicinal Chemistry|September 29, 2017
Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AMLAoli Wang, Xixiang Li, Cheng Chen, et al.
Oncotarget|June 21, 2016
Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)Feiyang Liu, Beilei Wang, Qiang Wang, et al.
Oncotarget|September 17, 2015
Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC CellsHong Wu, Aoli Wang, Wei Zhang, et al.
Oncotarget|April 16, 2016
Characterization of selective and potent PI3Kδ inhibitor (PI3KDIN- 015) for B-Cell malignancesXiaochuan Liu, Aoli Wang, Xiaofei Liang, et al.
Oncotarget|July 23, 2016
Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignanciesXiaochuan Liu, Aoli Wang, Xiaofei Liang, et al.
Pageof 18

Showing results (161-170 of 173) with videos related to

Sort By:
Pageof 18
European Journal of Medicinal Chemistry|June 20, 2017
Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitorsBeilei Wang, Yuanxin Deng, Yongfei Chen, et al.
European Journal of Medicinal Chemistry|October 15, 2018
Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemiaXuesong Liu, Beilei Wang, Cheng Chen, et al.
Journal of Medicinal Chemistry|February 1, 2017
Discovery of 2-((3-Acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow Kinase in the X Chromosome (BMX) Kinase InhibitorXiaofei Liang, Fengchao Lv, Beilei Wang, et al.
Journal of Medicinal Chemistry|August 23, 2016
Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I "Gatekeeper" Mutant of cKIT KinaseBinhua Li, Aoli Wang, Juan Liu, et al.
Oncotarget|September 15, 2016
Ibrutinib targets mutant-EGFR kinase with a distinct binding conformationAoli Wang, Xiao-E Yan, Hong Wu, et al.
Journal of Medicinal Chemistry|September 29, 2017
Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AMLAoli Wang, Xixiang Li, Cheng Chen, et al.
Oncotarget|June 21, 2016
Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)Feiyang Liu, Beilei Wang, Qiang Wang, et al.
Oncotarget|September 17, 2015
Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC CellsHong Wu, Aoli Wang, Wei Zhang, et al.
Oncotarget|April 16, 2016
Characterization of selective and potent PI3Kδ inhibitor (PI3KDIN- 015) for B-Cell malignancesXiaochuan Liu, Aoli Wang, Xiaofei Liang, et al.
Oncotarget|July 23, 2016
Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignanciesXiaochuan Liu, Aoli Wang, Xiaofei Liang, et al.
Pageof 18